Highlight

1. ClearMOA

1. Orexins bind and activate their associated G protein-coupled OX1Rs and OX2Rs and act on sleep-wake regulation.

2. Antagonism of the orexin system increases NREM and REM sleep, decreases anxiety- and panic-like behaviors, and inhibits the reinforcing and motivational properties of addictive drugs.

3. Orexin-A activates both OX1Rs and OX2Rs with approximately equal potency, while orexin-B preferentially activates OX2Rs.

4. OX1Rs and OX2Rs play differential roles in the regulation of REM sleep and NREM sleep. NREM sleep is mainly regulated by OX2Rs.

2. High selective dual inhibition.

The antagonistic effect of the asset on OX2R is better than that on OX1R.

3. Treat insomnia: Significantly increases NREM time, decreases NREM latency and wakefulness time without affecting REM timein rats and cynomolgus monkeys.

4. After 12h administration (light on), the asset has no effect on NREM or wakefulness, showing slight residual effectof the next day.

5. Good safety:

1) There is no significant correlation between the incidence of AEs and the dose.

2) No SAEs, no TEAE leading to early withdrawal from the test or death.

Research progress：

1.Asset has completedphase 1 trial.

2. Slightresidual effect of the next day

3. Good efficacy without affecting REM time.